CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study

Inclusion Criteria: * Ability to understand and willingness to sign an informed consent form * At least 18 years of age * Histologically confirmed advanced solid tumors * Patients must have grade 2 or 3 irAEs from at least one ICI-containing regimen. Both newly emerging and persistent irAEs are allowed. Systemic steroid therapy or any other form of immunosuppressive therapy for irAEs is allowed. The specific irAEs are * Grade 2-3 diarrhea/colitis: Patients with \>= 4 stools per day or moderate-severe increase in ostomy output compared to baseline but not life-threatening diarrhea * Grade 2-3 pneumonitis: Mild to moderate (grade 2) or severe (grade 3) symptoms (including hypoxia, shortness of breath, requiring oxygen) but not life-threatening respiratory compromise requiring urgent intervention (e.g., tracheostomy or intubation) * Grade 2-3 renal irAE: Creatine increased between 1.6-6.0 x upper limit of normal (ULN) or =\< 3.0 x baseline if baseline was abnormal, estimated glomerular filtration rate (eGFR) or creatinine clearance \>= 15 ml/min/1.73m\^2 but not life-threatening consequences or requiring dialysis * Grade 2-3 Hepatic irAE: AST/ALT/ALP levels 3-20 x ULN, and T bilirubin increased \<5 x ULN * Grade 2-3 skin rash: moderate (10-30% body surface area, BSA) to severe (\> 30% BSA) but not life-threatening skin lesions or Stevens-Johnson syndrome * Eastern Cooperative Oncology Group (ECOG) performance status \< 2 * Life expectancy of \>= 3 months at the time …